<DOC>
	<DOCNO>NCT00697814</DOCNO>
	<brief_summary>Prolactinomas usually associate hypogonadotropic hypogonadism sex . Clomiphene citrate well know selective estrogen receptor modulator increase gonadotropin secretion via hypothalamic-pituitary action . We conduct prospective , open label clinical trial CC evaluate effect revert persistent HH male patient prolactinomas dopaminergic agonist treatment .</brief_summary>
	<brief_title>Clomiphene Males With Prolactinomas Persistent Hypogonadism</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Prolactinoma</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<criteria>minimum followup 6 month DA therapy normal serum prolactin maximum DA dose ( 3.5 mg/week cabergoline 10 mg/day bromocriptine least 2 month ) serum total testosterone less 300ng/dl normal low LH FSH level discontinue testosterone replacement least 2 month . impossibility attend schedule visit irregular compliance DA treatment .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Hypogonadotropic hypogonadism</keyword>
	<keyword>Prolactinoma</keyword>
</DOC>